Viral Load Changes in Lymphoma Patients With HCV Infection After Chemotherapy
Serial Viral Load Changes and Hepatotoxicity in Lymphoma Patients With Hepatitis C Antibody After Chemotherapy Treatment: A Prospective Multicenter Observational Study and Long-term Retrospective Analysis
In last few years, most researches about hepatic complication after chemotherapy focused on hepatitis B virus (HBV). With adequate prophylaxis and monitor, HBV-related hepatitis flares can be prevented. In contrast, cancer patients with hepatitis C virus (HCV) infection are traditionally considered as relative safe to receive chemotherapy. However, two large retrospective studies recently showed that severe hepatitis could develop in 14-27% lymphoma patients with chronic HCV infection, including 3-4% hepatic failure. The risk factors to predict severe hepatitis are pre-treatment elevated ALT level and liver cirrhosis. Due to the lack of prospective studies, the dynamic changes of serum HCV RNA levels and the association of hepatitis are still unclear.
Some epidemiologic studies demonstrated an association between HCV infection and B-cell lymphoma. Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma and several reports showed higher prevalence of HCV infection among DLBCL patients than the controls. HCV infected DLBCL patients are reported to have distinct clinical characteristics, such as older, more with elevated LDH levels, and more with extra-nodal involvement. Regarding the impact of HCV infection on prognosis, the results are conflicting. Taiwan is an endemic area of HCV but there are limited reports addressing the clinical characteristics and prognosis in this unique population.
Therefore, the investigators initiate a prospective, multi-center observational study to clarify the dynamic association between serum HCV RNA levels and hepatitis in HCV-infected lymphoma patients treated with chemotherapy.
연구 개요
상태
연구 유형
등록 (예상)
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
설명
Inclusion Criteria:
- Newly diagnosed histologically proven malignant lymphoma
- Eligible subjects must be positive for anti-HCV Ab
- Age ≥ 20 years
- Planned to receive chemotherapy
- No recent chemotherapy and radiotherapy in the past one year. Pre-enrollment steroids for symptomatic relief are allowed but less than equivalent dose to prednisolone total 140 mg
- Left expectancy ≥ 3 months
- Signed informed consent
- ECOG 0-2
Exclusion Criteria:
- Patients not willing to receive chemotherapy
- Chronic hepatitis B infection (positive for HBsAg), but those with resolved HBV infection (positive for anti-HBc and negative for HBsAg) are allowed
- Other major systemic diseases, such as active infection, significant cardiac disease, neurologic deficit or psychiatric disorders, that the investigators consider to be at significant risk
- Known human immunodeficiency virus (HIV) infection
- Pregnant or breast-feeding woman
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
코호트 및 개입
그룹/코호트 |
|---|
|
HCV lymphoma patients with chemotherapy
Lymphoma patients who are positive for anti-HCV and are planning to receive chemotherapy for lymphoma
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
기간 |
|---|---|
|
Number of Participants with Increasing HCV RNA Level and Developing Hepatitis after Chemotherapy
기간: one year
|
one year
|
|
Number of Participants with Detectable Viremia and Developing Hepatitis after Chemotherapy
기간: one year
|
one year
|
|
Interval (months) between Peak HCV RNA Level and Hepatitis
기간: one year
|
one year
|
|
Increase (log) of HCV Viral Load between Baseline and after Chemotherapy
기간: one year
|
one year
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Number of Participants with Hepatitis after Chemotherapy
기간: one year
|
Hepatitis is defined as ALT level > 2.5X ULN
|
one year
|
|
Number of Participants with Severe Hepatitis after Chemotherapy
기간: one year
|
Severe hepatitis is defined as ALT level > 5X ULN or Bilirubin level > 3.0X ULN
|
one year
|
|
Number of Participants with Chemotherapy Interruption due to Hepatotoxicity
기간: one year
|
one year
|
|
|
Number of Participants with Early Stop of Chemotherapy due to Hepatotoxicity
기간: one year
|
one year
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (예상)
연구 완료 (예상)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- 103-7486B
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .